Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
WGS 
GeneDx Holdings Corp. (WGS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: WGS (3-star) is a STRONG-BUY. BUY since 31 days. Simulated Profits (21.58%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $123.75
1 Year Target Price $123.75
| 5 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 616.12% | Avg. Invested days 38 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.56B USD | Price to earnings Ratio 1770.71 | 1Y Target Price 123.75 |
Price to earnings Ratio 1770.71 | 1Y Target Price 123.75 | ||
Volume (30-day avg) 6 | Beta 2.1 | 52 Weeks Range 35.88 - 136.00 | Updated Date 09/14/2025 |
52 Weeks Range 35.88 - 136.00 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.07 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.39% | Operating Margin (TTM) 8.73% |
Management Effectiveness
Return on Assets (TTM) 1.05% | Return on Equity (TTM) 0.6% |
Valuation
Trailing PE 1770.71 | Forward PE - | Enterprise Value 3540445439 | Price to Sales(TTM) 9.83 |
Enterprise Value 3540445439 | Price to Sales(TTM) 9.83 | ||
Enterprise Value to Revenue 9.77 | Enterprise Value to EBITDA 65.23 | Shares Outstanding 28726200 | Shares Floating 20460557 |
Shares Outstanding 28726200 | Shares Floating 20460557 | ||
Percent Insiders 12.36 | Percent Institutions 110.61 |
Upturn AI SWOT
GeneDx Holdings Corp.
Company Overview
History and Background
GeneDx Holdings Corp. focuses on genomic testing, providing a range of clinical diagnostic tests. Detailed history and founding year information requires further research.
Core Business Areas
- Exome Sequencing: Comprehensive analysis of protein-coding regions to identify genetic variants associated with diseases.
- Genome Sequencing: Complete analysis of an individual's entire genome.
- Targeted Sequencing: Focuses on specific genes or regions of the genome associated with particular conditions.
- Rare Disease Testing: Diagnostic tests designed to identify the genetic causes of rare diseases.
Leadership and Structure
Leadership and organizational structure information requires further research from company filings.
Top Products and Market Share
Key Offerings
- Exome Sequencing: Diagnostic test to identify the genetic cause of undiagnosed conditions. Market share data is not readily available and requires dedicated research. Competitors include Invitae, Myriad Genetics, and Quest Diagnostics.
- Genome Sequencing: Comprehensive genomic analysis for diagnostic purposes. Market share data is not readily available and requires dedicated research. Competitors include Illumina, Pacific Biosciences.
- Rare Disease Testing: Specialized diagnostic tests for identifying genetic causes of rare diseases. Market share data is not readily available and requires dedicated research. Competitors include Centogene, Blueprint Genetics.
Market Dynamics
Industry Overview
The clinical genomics market is growing rapidly, driven by advancements in sequencing technology, increasing awareness of genetic diseases, and rising demand for personalized medicine.
Positioning
GeneDx is positioned as a provider of comprehensive genomic testing services with a focus on rare diseases.
Total Addressable Market (TAM)
The global genomics market is estimated to be substantial (billions of USD) and growing, though precise TAM figures require more specific research. GeneDx's positioning in rare disease testing puts it in a niche segment of the broader market.
Upturn SWOT Analysis
Strengths
- Comprehensive Test Portfolio
- Expertise in Rare Disease Genetics
- Established Customer Base
Weaknesses
- High Operating Costs
- Dependence on Reimbursement Policies
- Competition
Opportunities
- Expansion into New Markets
- Development of New Diagnostic Tests
- Partnerships with Pharmaceutical Companies
Threats
- Pricing Pressure
- Changes in Regulatory Landscape
- Emerging Technologies
Competitors and Market Share
Key Competitors
- NVTA
- MMSI
- DGX
- ILMN
Competitive Landscape
GeneDx competes in the clinical genomics market with varying degrees of overlap depending on specific tests. Key competitive advantages would depend on test price, speed, sensitivity and specificity. Additional, some advantages would be their relationships with payers.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends require accessing historical financial data and stock performance.
Future Projections: Future projections require accessing analyst reports and company guidance.
Recent Initiatives: Recent strategic initiatives require accessing the company's latest news releases and investor presentations.
Summary
GeneDx holds a position in a growing market. Its focus on rare diseases can provide a competitive advantage. It is important to maintain the cost efficiency and compete in a dynamic industry with evolving technologies and reimbursement pressures.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Market share data and financial information may not be current and are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GeneDx Holdings Corp.
Exchange NASDAQ | Headquaters Stamford, CT, United States | ||
IPO Launch date 2020-11-04 | President, CEO & Director Ms. Katherine A. Stueland | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 1000 | Website https://www.genedx.com |
Full time employees 1000 | Website https://www.genedx.com | ||
GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The company is headquartered in Stamford, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.